Nurix Therapeutics (NASDAQ:NRIX) Shares Down 4%

Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Free Report) was down 4% during mid-day trading on Wednesday . The stock traded as low as $13.77 and last traded at $14.26. Approximately 101,761 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 799,604 shares. The stock had previously closed at $14.86.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Royal Bank of Canada cut their target price on shares of Nurix Therapeutics from $24.00 to $22.00 and set an “outperform” rating on the stock in a research note on Friday, February 16th. Needham & Company LLC reissued a “buy” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday. HC Wainwright cut their target price on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. Wells Fargo & Company cut their target price on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, February 16th. Finally, Morgan Stanley boosted their price target on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.40.

View Our Latest Stock Analysis on Nurix Therapeutics

Nurix Therapeutics Trading Down 3.2 %

The stock’s fifty day simple moving average is $11.46 and its 200-day simple moving average is $8.90.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last posted its quarterly earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The business had revenue of $15.16 million during the quarter, compared to analyst estimates of $30.66 million. Nurix Therapeutics had a negative return on equity of 59.47% and a negative net margin of 186.98%. On average, equities research analysts predict that Nurix Therapeutics, Inc. will post -3.26 EPS for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,812 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $10.02, for a total transaction of $68,256.24. Following the completion of the transaction, the chief financial officer now owns 68,333 shares in the company, valued at $684,696.66. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 10,817 shares of company stock worth $100,256 in the last quarter. 6.20% of the stock is owned by company insiders.

Institutional Trading of Nurix Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Credit Suisse AG raised its position in Nurix Therapeutics by 7.9% during the second quarter. Credit Suisse AG now owns 15,619 shares of the company’s stock worth $197,000 after acquiring an additional 1,145 shares in the last quarter. Barclays PLC raised its position in shares of Nurix Therapeutics by 1.9% in the fourth quarter. Barclays PLC now owns 68,739 shares of the company’s stock valued at $709,000 after purchasing an additional 1,272 shares during the period. Virtus ETF Advisers LLC raised its position in shares of Nurix Therapeutics by 14.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,356 shares of the company’s stock valued at $107,000 after purchasing an additional 1,345 shares during the period. Rhumbline Advisers raised its position in shares of Nurix Therapeutics by 4.9% in the first quarter. Rhumbline Advisers now owns 33,511 shares of the company’s stock valued at $469,000 after purchasing an additional 1,573 shares during the period. Finally, Principal Financial Group Inc. raised its position in shares of Nurix Therapeutics by 16.3% in the first quarter. Principal Financial Group Inc. now owns 12,804 shares of the company’s stock valued at $114,000 after purchasing an additional 1,793 shares during the period.

About Nurix Therapeutics

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Featured Stories

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.